NCT03359590View on ClinicalTrials.gov

Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 21, 2018

Primary Completion Date

July 17, 2019

Study Completion Date

July 17, 2019

Conditions
Pharmacological Action
Interventions
DRUG

Sitagliptin 100 mg

The treatment consists of sitagliptin tablets (100 mg/day) for up to 24 weeks.

DRUG

Placebo

The treatment consists of placebo tablets for up to 24 weeks.

Trial Locations (1)

Unknown

Profil Institut für Stoffwechselforschung GmbH, Neuss

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Profil Institut für Stoffwechselforschung GmbH

INDUSTRY

NCT03359590 - Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients | Biotech Hunter | Biotech Hunter